- Home
- RVPHW vs BIOA Comparison
RVPHW vs BIOA Comparison
Compare RVPHW & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- BIOA
- Stock Information
- Founded
- RVPHW N/A
- BIOA 2015
- Country
- RVPHW United States
- BIOA United States
- Employees
- RVPHW 15
- BIOA N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- RVPHW Health Care
- BIOA Health Care
- Exchange
- RVPHW Nasdaq
- BIOA Nasdaq
- Market Cap
- RVPHW N/A
- BIOA N/A
- IPO Year
- RVPHW 2018
- BIOA 2024
- Fundamental
- Price
- RVPHW $0.14
- BIOA $4.06
- Analyst Decision
- RVPHW
- BIOA Hold
- Analyst Count
- RVPHW 0
- BIOA 3
- Target Price
- RVPHW N/A
- BIOA $18.00
- AVG Volume (30 Days)
- RVPHW N/A
- BIOA 1.3M
- Earning Date
- RVPHW N/A
- BIOA 11-07-2024
- Dividend Yield
- RVPHW N/A
- BIOA N/A
- EPS Growth
- RVPHW N/A
- BIOA N/A
- EPS
- RVPHW N/A
- BIOA N/A
- Revenue
- RVPHW N/A
- BIOA N/A
- Revenue This Year
- RVPHW N/A
- BIOA N/A
- Revenue Next Year
- RVPHW N/A
- BIOA N/A
- P/E Ratio
- RVPHW N/A
- BIOA N/A
- Revenue Growth
- RVPHW N/A
- BIOA N/A
- 52 Week Low
- RVPHW N/A
- BIOA $3.85
- 52 Week High
- RVPHW N/A
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- BIOA N/A
- Support Level
- RVPHW N/A
- BIOA N/A
- Resistance Level
- RVPHW N/A
- BIOA N/A
- Average True Range (ATR)
- RVPHW 0.00
- BIOA 0.00
- MACD
- RVPHW 0.00
- BIOA 0.00
- Stochastic Oscillator
- RVPHW 0.00
- BIOA 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.